Many people are handed an antibody result long before anyone explains it. This guide walks through what the words on the report mean, antibody by antibody, and what they do and do not tell us.
Antibody results only mean something alongside your symptoms, your examination, and your other tests. Your specialist puts those pieces together with you.
Antibodies are proteins your immune system makes to fight infection. In autoimmune diseases like myositis, the immune system also makes antibodies against parts of your own cells. These are called autoantibodies. They show up in a blood test, and in myositis they often follow patterns: certain antibodies tend to travel with certain types of the disease.
That is why your team orders a myositis antibody panel. The result can help confirm the type of myositis you have, suggest which parts of the body deserve a closer look, and sometimes guide treatment choices. It is one piece of the puzzle, alongside your story, your strength testing, and tests like muscle enzymes, EMG, MRI, and muscle biopsy.
The antibodies on your panel fall into two families. Myositis-specific antibodies are found almost only in people with myositis, so a true positive carries real weight. Myositis-associated antibodies are seen in myositis but also in related conditions such as lupus, scleroderma, and Sjogren's disease. They often point to an overlap between conditions rather than to one diagnosis.
Most people have one main antibody, or none. Having a particular antibody does not decide how severe your myositis will be. Two people with the same antibody can have very different journeys, and treatment is always based on the whole person, never on the panel alone.
There is no single standard panel. A small screen may check 3 or 4 antibodies, while extended panels check 15 or more. Different laboratories use different methods and different lists, and some antibodies are only tested at specialised labs, which can add weeks to the wait.
This is why two people can hold reports that look nothing alike, and why your specialist sometimes repeats or extends testing. If your first panel was small and questions remain, a wider panel can be sent. And if your myositis is already well explained by other tests, an extended panel may add nothing, so not everyone needs one.
Most panels report each antibody as negative, weak positive (sometimes "borderline" or "+"), or positive. A clear positive on a myositis-specific antibody, in a person whose symptoms fit, is meaningful information. A negative panel does not rule myositis out, and a weak positive is often less important than it looks.
Weak positives are frequent on these panels, and many turn out to be false positives, especially when the rest of the picture does not fit. Healthy people and people with other conditions can have them. If a weak positive on your report does not match your symptoms, your specialist may repeat the test, send a different method, or set it aside. Try not to read your future in one faint band on a printout.
Here are the antibodies most often reported on myositis panels, grouped by the patterns they tend to travel with. Remember: these are tendencies seen across many patients, not predictions about you.
Jo-1 is the most common myositis antibody. PL-7, PL-12, EJ, OJ, and KS are its rarer cousins.
Often linked with: Antisynthetase syndrome, a mix that can include muscle inflammation, arthritis, Raynaud's, fever, rough cracked skin on the hands ("mechanic's hands"), and inflammation in the lungs.
What it means for care: Your team checks your lungs with breathing tests and scans, even when your breathing feels fine, because lung inflammation can be quiet at first and treats best when found early.
These travel with the skin-and-muscle form of myositis. Each has its own pattern.
Often linked with: The classic dermatomyositis picture: the typical rashes with muscle weakness.
What it means for care: Mi-2 dermatomyositis often responds well to standard treatment.
Often linked with: Dermatomyositis with prominent skin disease. In adults, it is linked with a higher chance that a cancer is found around the time myositis appears.
What it means for care: Most adults with this antibody do not have cancer. The result tells your team to screen thoroughly, which is exactly how the uncommon case is caught early, when it is most treatable.
Often linked with: Dermatomyositis in both children and adults, including calcinosis, firm lumps of calcium that can form under the skin.
What it means for care: In adults, NXP-2 can also prompt more thorough cancer screening. In children it is a known juvenile dermatomyositis antibody and does not carry the adult cancer link.
Often linked with: A form of dermatomyositis where skin findings, painful ulcers, and joint pain can be prominent while muscle weakness is mild or absent. It can involve the lungs.
What it means for care: Because lung inflammation with this antibody can change quickly, your team monitors your breathing closely from the start and acts early. Close monitoring is the point, not a prediction.
Often linked with: A rarer dermatomyositis pattern where the rash often appears before the muscle symptoms.
What it means for care: Your team follows both skin and muscle over time, since the picture can evolve.
These travel with immune-mediated necrotising myopathy (IMNM), a form with marked weakness and very high CK.
Often linked with: Immune-mediated necrotising myopathy. It can follow statin use, but it also occurs in people who have never taken a statin.
What it means for care: This is different from ordinary statin muscle aches, and it does not settle just by stopping the statin. It responds to immune treatment, so recognising it matters.
Often linked with: A necrotising myopathy that can cause significant weakness and tends to be persistent.
What it means for care: Your team often plans combination treatment from early on, and follows your strength and CK closely.
One antibody is linked with IBM, though the diagnosis rests on the clinical picture and biopsy.
Often linked with: Inclusion body myositis. It is found in a portion of people with IBM, but also in some people with lupus or Sjogren's disease who do not have IBM.
What it means for care: A positive result supports the diagnosis; it does not prove it, and a negative result does not exclude it.
These are the overlap markers. They appear in myositis and in related autoimmune conditions.
Often linked with: Many autoimmune conditions. It is the most common companion antibody and usually appears alongside another antibody.
What it means for care: On its own, Ro52 does not diagnose myositis. When it accompanies an antisynthetase antibody, your team may keep an extra eye on the lungs.
Often linked with: Overlap conditions, where features of myositis mix with scleroderma or lupus, such as Raynaud's, skin tightening, or joint disease.
What it means for care: Your team looks for and manages the overlapping features, not only the muscle disease.
Some myositis antibodies, mainly TIF1-gamma and NXP-2 in adults with dermatomyositis, are linked with a higher chance that a cancer is present around the time myositis begins. It is natural to find this frightening, so here is the honest picture: most people with myositis, including most people with these antibodies, do not have cancer.
What the antibody result changes is how carefully we look. International guidelines now grade each person's situation and match the depth of screening to it, from routine age-appropriate checks to more detailed scans. Physicians at our Centre co-authored the national survey of how Canadian specialists screen for cancer in myositis, and the Centre follows a structured approach: screen thoroughly where the risk is higher, and spare people unnecessary tests where it is not.
If your report shows one of these antibodies, the right response is a careful screening plan made with your specialist, not fear. Finding nothing is the most common outcome. Finding something early is the reason we look.
Roughly one in three people with myositis has a panel where no antibody is found. This is called seronegative myositis. It does not mean your disease is milder, imagined, or less deserving of treatment. It means this particular test did not capture your form of the disease, which is exactly why diagnosis never rests on the panel alone. Your examination, muscle enzymes, EMG, MRI, and biopsy carry the diagnosis when the panel is silent, and science keeps identifying new antibodies, so some of today's "negative" patients will have a named antibody in the future.
Antibody results are reviewed by your Centre team together with everything else we know about you. Bring your questions to clinic, including the ones that feel small. Reading a report alone at night is the hardest way to learn what it means; going through it with your specialist is what the visit is for.
This guide is for learning, not medical advice. Antibody science is evolving, patterns described here are tendencies across many patients, and your own results may mean something different in your situation. Always review your results with your care team.
Written by Angelo Papachristos, BScPT, MBA, ACPAC, Advanced Practice Physiotherapist, Toronto Myositis Centre. Medically reviewed by Dr. Ophir Vinik, MD, FRCPC, Rheumatologist and clinical lead of the Myositis Clinic at St. Michael's Hospital. Last updated: August 2026. References are listed at the end of this page.
1. McHugh NJ, Tansley SL. Autoantibodies in myositis. Nature Reviews Rheumatology. 2018;14(5):290-302.
2. Betteridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. Journal of Internal Medicine. 2016;280(1):8-23.
3. Lundberg IE, et al. 2017 EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Annals of the Rheumatic Diseases. 2017;76(12):1955-1964.
4. Oldroyd AGS, et al. International guideline for idiopathic inflammatory myopathy-associated cancer screening. Nature Reviews Rheumatology. 2023;19(12):805-817.
5. Jekielek M, Nisenbaum R, Vinik O, Kassardjian CD. Idiopathic inflammatory myopathies and malignancy screening: a survey of current practices amongst Canadian neurologists and rheumatologists. Muscle & Nerve. 2025;72(3):502-508.